Biocon Opens First U.S. Generics Facility in New Jersey

Biocon Generics opened its first U.S. manufacturing plant in Cranbury, New Jersey, on October 4, 2025. The $30 million, 100,000-square-foot facility will produce 2 billion tablets annually, focusing on generic and complex oral solid dosage drugs. Approved by the U.S. FDA, it will create 150 skilled jobs. Executive Chairperson Kiran Mazumdar Shaw said, “This FDA-approved facility marks a key step in our global expansion, reaffirming our commitment to deliver affordable medicines to U.S. patients.” The plant strengthens Biocon’s U.S. presence and supports pharmaceutical innovation.